Mission and Research
Biba Cancer Research Foundation (BibaCRF) is a memorial not-for-profit organization. We research with the aim of discovering early cancer detection biomarkers and strategies to improve patient survival outcomes for brain and other hard-to-treat cancers.
Our Vision
To enable timely treatment and improved survival in cancer patients through preventative and early cancer detection strategies
Our Goal
Research into investigating cancer biology for relevant biomarkers and other detection strategies to enable early detection of malignancy in cancer patients. As a not-for-profit research institute, BibaCRF will collaborate with other researchers and support such research with the intent of sharing and publishing its findings.
Research Aims
To investigate data from current and emerging preventative, screening and diagnostic technologies e.g., CEA tests, liquid biopsies, imaging, etc., combined with bioinformatics studies of such cancer genomic datasets to discover, research and promote strategies for early cancer detection including, but not limited to, discovering biomarkers for early cancer detection, particularly for hard-to-treat cancers. Besides, internally discovered biomarkers, those already used in industry screening and in previous literature will also be researched to contextualize such biomarkers in terms of cancer types, stages, pathways, and role in cancer biology such as metabolism, cell cycle, autophagy, target for therapy, etc. This research will entail multi-disciplinary data science, in silico, in vitro and in vivo studies in collaboration with academic researchers, clinicians, and industry partners.
Planned Outcomes
To broadly disseminate research and publish findings on early cancer detection strategies to promote promising diagnostic and screening methodologies and consequently, enable timely treatment, and improved survival in cancer patients.
Tumour Suppressor p53
p53 is a tumour suppressor that is mutated in over 50% of cancers. It ensures cellular integrity by recognizing abnormal or cancerous DNA, in which case it triggers cell death. It is part of our system’s innate immunity and is regarded as the ‘Guardian of the Genome’. It is when p53 is dysfunctional that tumours can grow.
Our research is focused on discovering an effective p53-based therapeutic that boosts and where mutated, restores p53 function to specifically target and kill cancer cells.
As p53 is a common cancer target, upon gaining regulatory approvals for brain cancer treatment, we aim to test the approved therapeutic further for other cancers as well.
